Dabos Konstantinos John
Department of Hepatology, St Hohn's Hospital, Livingston EH54 6PP, West Lothian, United Kingdom.
World J Hepatol. 2024 Feb 27;16(2):112-114. doi: 10.4254/wjh.v16.i2.112.
In the present issue of the , Ferrassi examine the problem of liver fibrosis staging in chronic hepatitis C. They identify novel biomarkers in an effort to predict accurate fibrosis staging with the aid of the metabolome of Hepatitis C patients. Overall I think Ferrassi took a different approach in identifying fibrosis biomarkers, by looking at the patients' metabolome. Their biomarkers clearly separate patients from controls. They can also separate out, patients with minimal fibrosis (F0-F1 stage) and patients with cirrhosis (F4 stage). Obviously, if these biomarkers were to be widely used, tests for all the important metabolites would need to be readily available for use in hospitals or outpatient setting and that may prove difficult and above all, costly. Nevertheless, this step could eventually lead to a metabolomic approach for novel biomarkers of Fibrosis. Obviously, it would need to be validated, but could represent a step towards the Holy Grail of Hepatology.
在本期《 》中，费拉西研究了慢性丙型肝炎中肝纤维化分期的问题。他们识别新型生物标志物，试图借助丙型肝炎患者的代谢组来准确预测纤维化分期。总体而言，我认为费拉西在识别纤维化生物标志物方面采用了不同的方法，即观察患者的代谢组。他们的生物标志物能明显区分患者与对照组。还能区分出轻度纤维化患者（F0 - F1期）和肝硬化患者（F4期）。显然，如果这些生物标志物要广泛应用，针对所有重要代谢物的检测需要在医院或门诊环境中随时可用，而这可能会很困难，尤其是成本高昂。然而，这一步最终可能会导向一种用于纤维化新型生物标志物的代谢组学方法。显然，它需要经过验证，但可能代表着朝着肝病学的圣杯迈出了一步。
